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1156Contemporary Clinical Applications of
Coronary Intravascular Ultrasound
Intravascular ultrasound (IVUS) provides valuable information on the coronary vascular lumen and wall and has been
an important tool in the cardiac catheterization laboratory for over 2 decades. The major utility of IVUS relates to
optimizing stent deployment, particularly in complex lesions. In percutaneous coronary intervention with bare-metal
stents, IVUS guidance reduces restenosis. In percutaneous coronary intervention with drug-eluting stents, IVUS guid-
ance may reduce rates of stent thrombosis with little affect on restenosis. The beneﬁt of IVUS guidance is most im-
portant in complex lesion subsets, such as left main and bifurcation lesions, where studies suggest that IVUS guid-
ance may reduce mortality. Whereas IVUS luminal area measurements have been used to assess intermediate lesion
severity, recent studies have demonstrated that IVUS accurately identiﬁes nonischemic lesions for which percutane-
ous coronary intervention can be safely deferred, but cannot accurately predict hemodynamically signiﬁcant lesions
and should not solely be used to justify revascularization. In the current review, we focus on clinical applications of
IVUS in interventional cardiology. (J Am Coll Cardiol Intv 2011;4:1155–67) © 2011 by the American College of
Cardiology Foundationr
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(With its excellent imaging quality and spatial resolution,
intravascular ultrasound (IVUS) provides complementary
diagnostic information to angiography regarding lumen and
vessel dimensions, plaque burden and composition, and
arterial remodeling. Indeed, IVUS can identify lesions in
which revascularization can safely be deferred, guide thera-
peutic strategy in lesions requiring percutaneous coronary
intervention (PCI), and assess stent deployment. In the
current review, we focus on the clinical applications of IVUS
with a focus on the recently published literature.
IVUS Principles
There are 2 types of IVUS systems for clinical use: the
mechanical single-element rotating transducer and the
solid-state electronic phased array transducer. The 6-F
compatible mechanical systems offer a more uniform pull-
back and greater resolution due to the higher ultrasound
frequency. Mechanical systems are available commercially as
the 40-MHz iCross or Atlantis SR Pro catheters (Boston
Scientific, Santa Clara, California), the Revolution 45-
MHz catheter (Volcano Corp., Rancho Cordova, Califor-
nia), and the 40-MHz LipiScan IVUS (InfraReDx, Burl-
ington, Massachusetts). The solid-state phased array
transducer has 64 stationary transducer elements around the
tip that image at 20 MHz, and it is commercially available
as the 5-F– compatible Eagle Eye Catheter (Volcano
Corp.). Benefits of the solid-state catheter include enhanced
trackability due to the coaxial design and lack of nonuni-
form rotational distortion artifacts seen with rotational
systems.IVUS for Assessment of
Angiographic Intermediate Lesions
A major limitation of coronary angiography is that it fails to
accurately determine anatomy, as it produces a 2-dimensional
representation of a 3-dimensional coronary lumen. In addi-
tion, diffuse reference vessel disease, lesion foreshortening,
angulations, calcification, eccentricity, vessel overlap, and
streaming of contrast can complicate angiographic assess-
ment of lesion severity. As IVUS provides both accurate
lumen and vessel dimensions, it is therefore not surprising
that it has been shown to be more reproducible and accurate
than angiography for assessment of atherosclerotic disease
severity (1–3). Basic IVUS measurements for assessing
lesion severity are illustrated in Figure 1.
Non–left main lesions. Management of intermediate lesions
emains a therapeutic dilemma for interventional cardiolo-
ists. Even experienced interventional cardiologists cannot
ccurately assess the hemodynamic significance of interme-
iate or moderate lesions between 40% and 70% stenosis
sing angiographic assessment (1,3). In addition, significant
nter- and intraobserver differences in angiographic inter-
retation of disease severity have been reported (1).
Even though fractional flow reserve (FFR) is considered
he gold standard for intermediate lesion assessment (4–6),
everal studies have reported fairly good correlation between
natomic data by IVUS and ischemia by physiological
ssessments. In fact, FFR can be accurately predicted using
stablished equations and accurate 3-dimensional IVUS imaging
7). Early studies suggested that minimal lumen area
MLA)4 mm2 by IVUS had a diagnostic accuracy of 89%in identifying a coronary reserve flow 2.0 (8), whereas an
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1157MLA 4 mm2 correlated well with ischemia on single-
hoton emission computed tomography (9). This cutoff
alue of an MLA 4 mm2 also correlated moderately well
with an FFR 0.75 in a study of 53 intermediate lesions
from 43 patients, with a sensitivity and specificity of 92%
and 56%, respectively (10). Additionally, low event rates
were noted in 300 patients with intermediate lesions in
whom intervention was deferred for an IVUS MLA 4
mm2 (11). Based on these studies, many clinicians have used
an MLA cutoff value of 4.0 mm2 to determine if PCI was
warranted.
However, the limitation of a single IVUS MLA cutoff is
that the hemodynamic effects of a lesion are not only
dependent on MLA, but also on numerous other factors,
including lesion length, eccentricity, entrance and exit
angles and forces, reference vessel dimensions, and the
amount of myocardium subtended by the lesion. Not
surprisingly, other studies have found different MLA values
and a combination of other anatomic parameters to predict
FFR. In a study of 51 patients with intermediate stenosis,
the combination of an MLA 3 mm2 and an area stenosis
60% best predicted FFR 0.75 (12). Recently, in an
analysis of 236 intermediate lesions from 201 patients, the
best cutoff value of MLA to predict an FFR 0.80 was 2.4
mm2 (sensitivity of 90% and specificity of 60%) (13).
Furthermore, in 92 intermediate lesions from 84 patients,
MLA of 2.8 mm2 and 3.2 mm2 best correlated with an
FFR 0.75 and 0.80, respectively (14). Finally, in 94
patients with intermediate lesions with smaller vessels (ref-
erence diameter 3.0 mm), the best predictors for FFR
0.75 were MLA 2.0 mm2 (sensitivity of 82% and
pecificity of 81%), plaque burden80% (sensitivity of 88%
nd specificity of 79%), and lesion length 20 mm (sensi-
ivity of 64% and specificity of 79%) (15).
Taken together, these studies suggest that an MLA 4.0
m2 can accurately identify nonischemic lesions for which
PCI can be safely deferred. By contrast, an MLA4.0 mm2
does not accurately predict a hemodynamically significant
lesion and should not be used to justify revascularization.
The significance of an MLA 4.0 mm2 should be consid-
red in the context of reference vessel size, lesion length,
rea stenosis, plaque burden, and area of myocardium at risk
13–15). Whereas FFR is the preferred tool for intermediate
esion assessment, an algorithm for contemporary IVUS-
uided PCI of non–left main lesions is proposed in Figure 2.
Left main lesions. As revascularization with coronary artery
bypass grafting, compared with medical therapy, for signif-
icant left main coronary artery lesions has been shown to
reduce mortality, the accurate assessment of intermediate
left main lesions is important to optimize outcomes (16).
Furthermore, the angiographic assessment of stenosis sever-
ity in the left main is challenging, as this segment is short,
often calcified, with diffuse disease involving the ostium or
bifurcation (Fig. 3).IVUS has been widely used in the assessment of inter-
mediate left main coronary artery lesions (17). In a study of
55 patients with moderate left main stenosis, an MLA
cutoff value of 5.9 mm2 (sensitivity of 93% and specificity of
5%) and a minimal lumen diameter of 2.8 mm (sensitivity
f 93% and specificity of 98%) best correlated with FFR
0.75 (18). Additionally, in 354 patients with intermediate
eft main stenoses, an MLA value 6.0 mm2 identified
atients at low risk for adverse events with deferred revas-
ularization (19).
Meanwhile, other IVUS studies have defined significant
eft main lesions by different MLA cutoff values. Unpub-
ished data from 47 patients with intermediate left main
esions suggested an MLA 4.5 mm2 best correlated an
FFR 0.80 (predictive accuracy 83%) (Seung-Jung Park,
unpublished data, 2011). Further-
more, in 214 patients with inter-
mediate left main lesions, an
MLA 7.5 mm2 was associated
with good outcomes, whereas pa-
tients who were medically man-
aged with an MLA 7.5 mm2
had poor outcomes (20). Never-
theless, this nonrandomized obser-
vational study might have had con-
founding factors driving outcomes;
therefore, definitive conclusions
from this study are difficult regard-
ing an MLA 7.5 mm2.
Given the limitations of a sin-
gle MLA to predict hemody-
namic significance of a stenosis,
FFR should be the preferred mo-
dality for intermediate left main
lesion assessment. However, if
IVUS is used, revascularization
may be deferred in patients with
left main MLA 6.0 mm2 as
hese values are not associated
ith ischemia and have favorable outcomes. For an MLA
6.0 mm2, consideration should be given to performing FFR
r noninvasive stress testing before revascularization, as there
ay be discrepancy with the IVUS MLA cutoff (4.5 to 6.0
m2) that correlates with FFR (Fig. 4) (17–20).
VUS to Guide PCI
The major use of IVUS is to plan interventional strategy and
optimize stent deployment. Pre-intervention IVUS accu-
rately assesses reference lumen dimensions and lesion length
for appropriate stent sizing. Additionally, identification of
superficial calcium by IVUS can lead to pre-stent rotational
Abbreviations
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AHA  American Heart
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occlusion
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1158Heart Association [ACC/AHA] PCI guidelines, IIa indi-
cation) (21). Furthermore, when large thrombus burdens are
detected by IVUS, operators may alter anticoagulant ther-
apies or consider mechanical thrombectomy. Post-stent
IVUS assessment may detect complications of PCI and
suboptimal stent deployment and is supported by the
ACC/AHA PCI guidelines (IIa indication) (21).
IVUS-guided PCI with BMS. Several IVUS characteristics
have been associated with increased adverse events after PCI
with bare-metal stent (BMS), including smaller minimal
stent area (MSA), stent underexpansion, persistent edge
dissections, incomplete stent apposition (ISA), and incom-
plete lesion coverage (22–27). Of these, smaller MSA is
most commonly associated with target vessel failure at
follow-up (26,28–32). In a registry of 1,706 patients, the
risk of restenosis with BMS decreased 19% for every 1-mm2
increase in MSA (31). Although studies have differed as to
the best cutoff value for MSA (ranging from 6.5 to 9.0
mm2), larger post-PCI areas consistently predict lower rates
of restenosis (26,28–32). This is likely due to 2 major
mechanisms. First, even in optimally deployed stents,
smaller stents, compared with larger diameter stents, have
greater restenosis rates, as similar amounts of neointimal
Figure 1. Basic IVUS Measurements
A is from the proximal reference, and B is from the most severe stenosis repre
which compares the stenosis lumen to the reference lumen. This is in contrast
nal elastic membrane (EEM). Due to arterial remodeling, the plaque burden is
stenosis severity. MLA  minimal lumen area; RLA  reference lumen area.hyperplasia leads to smaller lumen areas. Second, smallerMSA can represent stent underexpansion, which can be
treated with appropriate post-dilation.
Stent underexpansion is defined as an area of inade-
quately expanded stent compared with the adjacent refer-
ence segment. Although, a consensus definition of adequate
expansion is lacking, a simplified version of the MUSIC
(Multicenter Ultrasound Guided Stent Implantation in the
Coronaries) criteria can be used to define adequate expan-
sion (80% average reference cross-sectional area) (Table 1)
(33). Most trials have used similar definitions and have
favored an IVUS-guided PCI strategy with BMS over an
angiography-guided strategy (24,34–40). An example of
stent underexpansion is illustrated in Figure 5.
The clinical benefit of an IVUS-guided BMS PCI
strategy is largely driven by reductions in restenosis and
target vessel revascularization (TVR), without significant
benefits in death or myocardial infarction. This was illus-
trated in a recent meta-analysis of 2,193 patients from 7
randomized trials, where an IVUS-guided PCI strategy
with BMS reduced TVR (13% vs. 18%, p  0.001)
compared with angiography-guided PCI strategy with
similar rates of death (2.4% vs. 1.6%, p  0.18) and
myocardial infarction (3.6% vs. 4.4%, p  0.51) (41). The
g the minimal lumen area. C illustrates the calculation of area stenosis,
aque burden (D), which compares the stenosis lumen to the stenosis exter-
ually the same as area stenosis and therefore should not be used to assesssentin
to pl
not usmechanism for the reduction in restenosis with IVUS-
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1159guided BMS PCI likely relates to the more frequent use
of post-dilation with larger diameter balloons and at
higher pressures, resulting in more adequately expanded
stents with larger MSA (24,36).
Taken together, these studies suggest “bigger is better” in
PCI with BMS, with the caveat that stent overexpansion
and arterial overstretch might also induce arterial injury and
has been associated with a higher degree of neointimal
hyperplasia in several small studies (42,43).
IVUS-guided PCI with DES. RESTENOSIS. In contrast to the
literature supporting an IVUS-guided strategy in PCI with
BMS, studies evaluating IVUS guidance in PCI with
drug-eluting stent (DES) have largely been limited to
retrospective investigations, with no randomized controlled
trials demonstrating improved clinical outcomes. A recent
retrospective analysis of 250 patients undergoing PCI with
DES showed no significant difference in restenosis with and
without optimal stent expansion as defined by MUSIC
criteria (44). The only published randomized trial to inves-
tigate an IVUS-guided strategy in PCI with DES, HOME
DES (Long-Term Health Outcome and Mortality Evalu-
ation After Invasive Coronary Treatment Using Drug
Figure 2. Proposed IVUS Criteria for Assessment of Intermediate
Non–Left Main Coronary Lesions (40% to 70% Stenosis)
Invasive or noninvasive physiological evaluation is recommended to assess
the signiﬁcance of intermediate coronary lesions (4). In case intravascular
ultrasound (IVUS) is used, the following is a proposed algorithm based on
the recent literature (8–11,15). Most intermediate lesions with a MLA 4.0
cm2 are nonsigniﬁcant and intervention may be safely deferred (8–11). For
minimal lumen area (MLA) 4.0 mm2, physiological evaluation is recom-
mended. If physiological evaluation is unavailable, the signiﬁcance of an
MLA 4.0 mm2 should be considered in the context of reference vessel
size, lesion length, area stenosis, plaque burden, and area of myocardium
at risk. Intermediate lesions are more likely to be hemodynamically signiﬁ-
cant in larger reference vessels when area stenosis is 60% to 70%, plaque
burden is 80%, and lesion length is 20 mm (10,18). FFR  fractional
ﬂow reserve.Eluting Stents with or without the IVUS Guidance) study,randomized 210 patients to an IVUS-guided PCI strategy
versus an angiography-guided strategy (45). In this study,
the IVUS-guided strategy led to more frequent post-
dilations, higher balloon inflation pressures, and larger
balloon sizes, but it did not result in lower rates of TVR or
major adverse cardiac events. However, this study was
considered underpowered to detect differences in clinical
events. Moreover, the definition of optimal stent deploy-
ment was less rigorous than for other trials. Optimal stent
deployment was defined as complete apposition of the stent
struts, no edge dissections, and adequate stent expansion,
which was defined as either MSA 5.0 mm2 or 90% of
the distal reference lumen area.
Similar findings were noted in the recently presented
AVIO (Angiography Versus IVUS Optimization) study,
which also compared IVUS-guided and angiography-
guided PCI strategies with DES in 284 patients with
complex lesions (long lesions, bifurcations, chronic total
occlusions [CTO], and small vessels) (46). In AVIO, novel
(and more aggressive) criteria for optimal stent deployment
were used (Table 1). Although this IVUS-guided strategy
led to larger stent dimensions, this did not translate into
improved clinical outcomes at 9 months in this study.
However, clinical follow-up was incomplete and the study was
possibly underpowered to detect differences in restenosis.
STENT THROMBOSIS. Whereas IVUS-guided PCI in DES
ay not influence rates of restenosis, there is increasing
vidence that this strategy may reduce rates of stent throm-
osis. In a recent propensity-matched analysis of 884
atients undergoing PCI with DES, an IVUS-guided
trategy was associated with reduced rates of stent throm-
osis at both 30 days (0.5% vs. 1.4%, p  0.046) and 12
months (0.7% vs. 2.0%, p  0.014) when compared with an
angiography-guided strategy (47). In addition, IVUS guid-
ance was found to be an independent predictor of freedom
from stent thrombosis. The mechanism of this benefit may
be related to the identification and treatment of suboptimal
stent deployment. Indeed, several studies have suggested
that factors associated with stent thrombosis include edge
dissections, stent underexpansion, ISA, incomplete lesion
coverage, geographic miss, tissue protrusion, and residual
thrombus (48–55). Of these IVUS findings, edge dissec-
tions, stent underexpansion, and ISA have been the most
extensively investigated.
EDGE DISSECTIONS. Early after PCI, persistent higher-
grade dissections on angiography classified as National
Heart, Lung, and Blood Institute types B to F dissections
have been associated with higher rates of acute thrombosis
(22,56). Therefore, prolonged balloon inflations or deploy-
ment of a second stent are commonly used to treat these
angiographically apparent higher-grade dissections. The
incidence of persistent edge dissections by IVUS after DES
implantation is approximately 10%, of which almost 40%
are not detected by angiography (57). High-grade edge
w
e
1
e
p
viatio
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 1 , 2 0 1 1
N O V E M B E R 2 0 1 1 : 1 1 5 5 – 6 7
McDaniel et al.
IVUS in Interventional Cardiology
1160dissections, defined by IVUS as lumen area narrowing 4
mm2 or dissection angle 60°, have been associated with
higher rates of early stent thrombosis (55) and, therefore,
should be stented. However, low grade and angiographically
silent edge dissections may not be associated with higher
rates of adverse events (57–59), and there is no consensus on
their optimal management.
STENT UNDEREXPANSION. Smaller stent areas have consis-
tently been associated with higher rates of stent thrombosis,
implicating stent underexpansion in the pathogenesis of
both early and late stent thrombosis. In 7,484 patients
undergoing PCI with BMS, early thromboses were most
commonly associated with inadequate post-procedure lu-
men area, either alone or in combination with dissection,
thrombus, or prolapse (23). Similarly, several small studies
in the DES era have demonstrated that stent underexpan-
sion and smaller MSAs (usually 5.0 mm2) are associated
ith early and late stent thrombosis. In 15 patients with
arly stent thrombosis after DES implantation, MSA (4.3 
Figure 3. Angiographic Intermediate Ostial Left Main Lesion
An example of an angiographic intermediate ostial left main lesion (A) that w
mild plaque with signiﬁcant negative remodeling resulting in an MLA of 8.9 m
The patient was medically managed and revascularization was deferred. Abbre.6 mm2 vs. 6.2  1.9 mm2, p  0.001) and optimal stentxpansion (65 18% vs. 85 14% of reference lumen area,
 0.001) were significantly lower than for a matched
control group without thrombosis (50). Similar findings
have been noted in other small series of patients with DES
thrombosis (51,52). Based on these limited data, and until
larger studies are performed, it seems reasonable to target
optimal DES expansion defined similarly to BMS criteria
(80% average reference cross-sectional area).
ISA. ISA is defined as the absence of contact between the stent
struts and the lumen wall and can occur acutely after stent
deployment (acute ISA) or develop over time (late-acquired
ISA). Acute ISA is almost always due to suboptimal stent
implantation (Fig. 6). The frequency of acute ISA has been
reported to be approximately 10% (60). Although, acute ISA is
associated with variable rates of persistent ISA at follow-up
(61,62), somewhat surprisingly, it appears not to be associated
with increased cardiac events at 1 year (49,60,63,64).
There are mixed data regarding the risk of stent throm-
bosis associated with late ISA. Late ISA may either be due
stigated by FFR (B) and IVUS (C, D). FFR was 0.88, and IVUS demonstrated
he red arrows (A) indicate the location of IVUS frames displayed in C and D.
ns as in Figures 1 and 2.as inve
m2. Tto persistence of acute ISA (late-persistent ISA) or the
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1161development of new ISA in regions that were previously
apposed (late-acquired ISA) (Fig. 7). The mechanism for
late-acquired ISA is thought to be related to either positive
remodeling of the vessel, resolution of thrombus present at
the time of the initial stent deployment, or delayed-type
hypersensitivity reaction (48,65). The incidence of this late
ISA has been shown to be 4 times more common in patients
receiving DES versus BMS (54,66).
Several studies suggest that late ISA is associated with
increased rates of stent thrombosis. In the initial study by
Cook et al. (49), the rate of late ISA was significantly higher
in patients with DES thrombosis than in control patients
without stent thrombosis (77% vs. 12%, p  0.001).
owever, segments with thrombosis were also associated
ith longer lesions, longer stents, more stents per lesion,
ower stent expansion index, and more stent overlap, mak-
Figure 4. Proposed IVUS Criteria for the Assessment of
Intermediate Left Main Coronary Lesions (30% to 60% Stenosis)
FFR remains the gold standard for the hemodynamic assessment of the
intermediate left main lesions. However, if IVUS is used, it is reasonable to
defer revascularization in patients with left main with an MLA 6.0 mm2.
For an MLA 6.0 mm2, consideration should be given to performing FFR
or noninvasive stress testing before revascularization as there may be dis-
crepancy in the best IVUS MLA cutoff that correlates with FFR. Abbrevia-
tions as in Figures 1 and 2.
Table 1. IVUS Criteria for Optimal Stent Deployment
MUSIC Criteria
● Complete apposition of stent ● Minim
● Adequate stent expansion ● The no
and mMSA 90% of the average reference lumen area or 100% of reference
segment with the lowest area when the MSA is 9 mm2
or
MSA 80% of the average reference lumen area or 90% of reference
segment with the lowest area when the MSA is 9 mm2
1. Distal
2. Proxim
3. In-ste
● Symmetrical stent expansion Deﬁned by minimum lumen diameter
divided by maximum lumen diameter 0.7
The criteria for optimal stent deployment used in the MUSIC (33) and AVIO (46) studies.AVIO Angiography Versus IVUS Optimization study; IVUS intravascular ultrasound; MSAminimaling definitive conclusions about the importance of late ISA
in this setting difficult. Most recently, in a meta-analysis of
5 trials, patients with late ISA (n  228) were associated
with an increased risk of stent thrombosis compared with
patients without late ISA (n 1,852) (odds ratio: 6.51, 95%
confidence interval: 1.34 to 34.91, p  0.02) (54). By
ontrast, other studies have not found this relationship
60,63,64,66–68). In a pooled study of 1,580 patients
nrolled in the IVUS substudies of multiple TAXUS
tent trials, there were 36 cases of late-acquired ISA at
-months follow-up, which were not associated with
ncreased rates of stent thrombosis or major adverse
ardiac events over the ensuing 2 years (60). In total,
hese studies suggest that at present, the results are
nconclusive as to the relationship between ISA and
ong-term adverse outcomes in DES. Regardless, most
perators would strive to achieve full apposition of all
tent struts after stent deployment.
IVUS-guided PCI in unprotected left main lesions. In unpro-
tected left main coronary artery PCI, the adverse consequences
related to suboptimal stent deployment are more dramatic,
and, as such, IVUS guidance may be of particular importance
in this lesion subset. The largest study to date investigating
IVUS guidance in left main PCI was the recently published
propensity score matching analysis of 210 matched patients
undergoing unprotected left main PCI from the multicenter
MAIN-COMPARE (Revascularization for Unprotected Left
Main Coronary Artery Stenosis: Comparison of Percutaneous
Coronary Angioplasty Versus Surgical Revascularization) trial
(69). In this analysis, there was a trend toward lower 3-year
mortality with an IVUS-guided strategy versus angiography
alone (6.0% vs. 13.6%, p  0.063). Interestingly, in the 145
matched-patient subgroup receiving DES, the 3-year inci-
dence of mortality was significantly lower in the IVUS-guided
group (4.7% vs. 16.0%, p 0.048). It has been postulated that
the mechanism of benefit is related to reduced rates of sudden
cardiac death related to late stent thrombosis. It should be
noted that the risk of myocardial infarction and TVR were not
influenced by IVUS guidance, and the mortality benefit was
AVIO Criteria
-stent area 70% of the balloon cross-sectional area used to post-dilate the stent
pliant post-dilation balloon size selected according to the average of the maximum
media-to-media diameter at the following points:
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1162not found in patients undergoing PCI with BMS. Overall,
these data suggest that IVUS guidance is advocated for left
main PCI with DES.
IVUS-guided PCI for bifurcation lesions. Pre-intervention
IVUS can assist in the optimal selection of bifurcation PCI
strategy, particularly by assessing plaque morphology and
distribution at the side branch ostium. Currently, compared
with routine 2-stent strategies, a single-stent strategy with
provisional side branch intervention has become the favored
approach for most bifurcation lesions due to reduced cardiac
events (70). In a recent propensity-matched analysis of
patients undergoing PCI of non–left main bifurcations with
DES using predominantly a single-stent strategy, an IVUS-
guided PCI strategy (n  487) was associated with larger
post-stent lumen diameters in both the main vessel and side
branch than an angiography-guided PCI strategy was (n 
487) (71). Importantly, IVUS guidance was associated with
lower rates of death or myocardial infarction than angiog-
raphy guidance (3.8% vs. 7.8%, p  0.03).
Pre-intervention IVUS of the side branch ostium may also
be useful to predict the likelihood of side branch compromise
due to plaque and/or carina shift after single-stent deployment
in the main branch (72). Recently, in 90 bifurcation lesions, a
pre-intervention MLA of 2.4 mm2 in the side branch could
ccurately predict a nonischemic post-intervention FFR
0.80) in the side branch (predictive value of 98%) after main
ranch stent deployment. However, an MLA2.4 mm2 could
ot accurately predict side branch compromise resulting in an
schemic FFR (predictive value of 40%).
At present, IVUS guidance is advocated in bifurcation
esion PCI with DES. If the pre-intervention side branch
LA is2.4 mm2, provisional side branch PCI can usually
Figure 5. Stent Underexpansion
An example of stent underexpansion in the mid stent at an area of calciﬁed pe deferred. However, if the side branch MLA is 2.4 rm2, clinical judgment and/or side branch FFR should be
considered to guide provisional side branch intervention.
IVUS-guided PCI for in-stent restenosis. In PCI for in-stent
estenosis, IVUS can assist in the differentiation of resteno-
is related predominantly to intimal hyperplasia versus
echanical complications, such as stent fracture or stent
nderexpansion. An IVUS-guided high-pressure angio-
lasty with a noncompliant balloon is often performed when
tent underexpansion is the major mechanism for restenosis
o avoid deployment of a second stent, especially with DES
estenosis. Balloon-alone angioplasty may also be appropri-
te in the presence of very focal lesions due to neointimal
yperplasia in both BMS and DES. In patients with diffuse
r proliferative in-stent restenosis of either BMS or DES, a
econd DES is often warranted. The use of IVUS to guide
CI in patients with restenosis is supported in the ACC/
HA PCI guidelines (IIa indication) (21).
IVUS-guided PCI for CTO. In CTO, antegrade recanalization
approaches often result in subintimal guidewire tracking. In small
series, operators have used IVUS imaging from the false lumen to
guide re-entry of the wire into the true lumen (73–75). Addition-
ally, in a small series of 31 CTO lesions (of which 22 were
previous failed attempts), successful recanalization was achieved in
100% of cases using a modified retrograde IVUS-guided approach
(76). Regardless of approach, once the CTO is crossed, IVUS
provides important information regarding reference vessel size,
plaque distribution and composition, as well as the adequacy of
stent deployment.
IVUS-guided PCI for saphenous vein graft lesions. IVUS
uidance during saphenous vein graft PCI may be particu-
arly important as saphenous vein grafts are often larger
ized than native vessels, making angiographic size assess-
ent more difficult. Indeed, oversized stents (stent to
(B). The proximal stent illustrates symmetrical stent expansion (A).eference ratio1.0) result in greater rates of periprocedural
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1163myocardial necrosis and distal embolization without reduc-
ing 9-month revascularization rates (77,78). In addition,
stent oversizing may result in graft perforation. Therefore, it
is reasonable to use IVUS to select appropriately sized stents
for saphenous vein graft PCI.
Radiofrequency IVUS
The addition of radio frequency backscatter signal analysis
allows for improved characterization of plaque composition.
Currently, there are 3 available software programs for plaque
composition assessment: 1) virtual histology IVUS (VH–
IVUS) (Volcano Corp.); 2) iMAP (Boston Scientific); and
3) Integrated Backscatter IVUS (IB-IVUS) (YD Co., Ltd.,
Nara, Japan). VH-IVUS has been compared with actual
histology from directional coronary atherectomy specimens
(79), coronary arteries from ex-planted hearts (80), and
carotid endarterectomy section (81) with overall moderate
predictive accuracies (80% to 94%). Similar validation stud-
Figure 6. Acute Incomplete Stent Apposition
Angiogram (A) of an example of acute incomplete stent apposition found imm
left anterior descending coronary artery of a patient, as well as the post-dilatioies have been performed for iMAP and IB-IVUS (82). MMajor limitations of the current radiofrequency-based
IVUS imaging technologies include the inability to accu-
rately detect thrombus and characterize plaque behind
calcium due to acoustic shadowing (83). In addition, the
accuracy of these 3 IVUS platforms to detect thin-cap fibro-
atheromas is limited by resolution, which does not allow for the
detection of cap thickness 65 m (82,84). In an ex vivo
utopsy study, IB-IVUS provided higher diagnostic accuracy
or tissue characterization than VH-IVUS (85).
The ability of the combination of grayscale IVUS and radio
requency backscatter analysis to predict the site of future
oronary events was evaluated in the PROSPECT (Providing
egional Observations to Study Predictors of Events in the
oronary Tree) trial (86). In PROSPECT, 697 patients
resenting with acute coronary syndromes were enrolled and
nderwent PCI of all culprit lesions followed by 3-vessel VH-
VUS imaging. At 3-year follow-up, nonculprit VH-IVUS de-
ned thin-cap fibroatheromas with a plaque burden 70% and
ely post stent implantation by intravascular ultrasound (IVUS) (B) in the
iography (C) and IVUS (D) of the same location.ediatLA 4.0 mm2 had an 18% major adverse cardiac events rate
mplet
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1164(driven largely by revascularization). The PROSPECT trial sug-
gests that the addition of radio frequency backscatter analysis to
grayscale IVUS might provide incremental prognostic informa-
tion, but further studies are warranted to investigate this hypoth-
esis. At present, PCI of nonsignificant lesions based on plaque
composition alone is not justified.
Future Perspectives
In the near future, catheters with multiple imaging modalities
may be combined for more comprehensive assessment of
atherosclerosis. Optical coherence tomography has higher spa-
tial resolution (10 to 12 m) than conventional IVUS (120
m) and might provide more detailed assessment of the lumen
surface, including cap thickness and regional stent strut assess-
ment (84). High-frequency IVUS catheters are also under
development that may provide similar resolution to conven-
tional optical coherence tomography. Other imaging modali-
ties, such as near-infrared spectroscopy, have also been devel-
oped to detect lipid composition, and combined near-infrared
spectroscopy and IVUS platforms have emerged. In addition,
forward-looking IVUS systems are under investigation, which
may assist in the percutaneous treatment of CTO (87).
Summary
Although, IVUS is not the imaging modality of choice for
assessing intermediate lesion severity, it has an important
role in guiding stent deployment, particularly for complex
lesions such as bifurcations, left main, CTO, in-stent
restenosis, and saphenous vein graft lesions. It is important
for the clinicians to have a thorough understanding of the
Figure 7. Late Incomplete Stent Apposition
Angiography (A) and IVUS (B) studies of an incomplete stent apposition using
presenting with an acute coronary syndrome. Although there was no baseline
likely undersized at the initial stent deployment and represents persistent incoexisting clinical applications of IVUS to best integrate novelimaging tools into clinical practice in the cardiac catheter-
ization laboratory. Furthermore, new criteria specific to each
novel imaging modality will have to be developed and
validated before appropriate clinical application.
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